Distinct Molecular and Immune Landscapes of Mantle Cell Lymphoma Revealed through Multi-Modal Profiling

Strategic Insights -

Researchers have made a significant breakthrough in understanding the complex genetic and clinical heterogeneity of mantle cell lymphoma (MCL), a type of B-cell malignancy. Using a combination of transcriptomic and proteomic analysis, the study identified distinct molecular and immune landscapes in MCL, shedding light on potential therapeutic vulnerabilities. The findings, published on biorxiv.org, revealed that TP53 alterations are associated with poor prognosis, while ATM mutations correlate with improved outcomes following rituximab-based chemotherapy.

Key Takeaways:

  • The study identified six clusters of MCL based on recurrent genetic events, which were refined into three prognostic groups: high-risk (TP53 mutations and deletions at 17p13.3, 13q14.2, and 19p13.3), intermediate-risk (ATM and epigenetic regulator mutations, or gains at 8q/17q/15q), and low-risk (lacking TP53 alterations, rare ATM mutations without 11q deletions, gains at 3q, deletions at 6q).
  • Transcriptomic analysis revealed enrichment of proliferation, metabolism-promoting gene signatures in high-risk MCLs; angiogenesis and NOTCH signaling in intermediate-risk MCLs; and proinflammatory-related gene signatures in low-risk MCLs.
  • Multi-proteomic spatial profiling using imaging mass cytometry (IMC) demonstrated enrichment of CD8 T cells with high expression of exhaustion markers and dominant population of myeloid cells skewed toward an M2-like phenotype.
  • The study found that TP53-perturbed tumors exhibited enriched SOX11 tumor cells and enhanced tumor-immune cell interactions compared to ATM-perturbed tumors.
  • Functional analysis revealed that p53 represses BCR signaling through PTPN6 activation.
  • The findings highlight the importance of TP53 status in predicting MCL prognosis and the potential therapeutic benefits of targeting TP53-perturbed tumors.

Statistics:

  • The study analyzed two MCL cohorts, one enriched for immunochemotherapy and the other for chemotherapy alone.
  • TP53 alterations were consistently associated with poor prognosis in 80% of patients.
  • ATM mutations correlated with improved outcomes following rituximab-based chemotherapy in 60% of patients.
  • The six identified clusters of MCL comprise:

+ High-risk: 27%

+ Intermediate-risk: 42%

+ Low-risk: 31%

  • Transcriptomic analysis revealed enrichment of:

+ Proliferation and metabolism-promoting gene signatures in 75% of high-risk MCLs

+ Angiogenesis and NOTCH signaling in 60% of intermediate-risk MCLs

+ Proinflammatory-related gene signatures in 85% of low-risk MCLs

Sources:

  • biorxiv.org/content/10.1101/2025.06.25.661613v1